Incyte (INCY) PT Set at $85.00 by Raymond James Financial

Incyte (NASDAQ:INCY) has been assigned a $85.00 target price by equities research analysts at Raymond James Financial in a report released on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Raymond James Financial’s target price indicates a potential upside of 32.77% from the company’s previous close.

Other equities research analysts have also issued reports about the stock. Nomura reiterated a “buy” rating on shares of Incyte in a research note on Thursday, February 1st. BMO Capital Markets reiterated a “buy” rating and set a $172.00 price target on shares of Incyte in a research note on Wednesday, January 3rd. William Blair reiterated a “market perform” rating on shares of Incyte in a research note on Friday. ValuEngine upgraded shares of Incyte from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Finally, Guggenheim reiterated a “neutral” rating on shares of Incyte in a research note on Friday. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Incyte has an average rating of “Buy” and an average target price of $131.03.

How to Become a New Pot Stock Millionaire

Shares of INCY opened at $64.02 on Friday. Incyte has a twelve month low of $63.43 and a twelve month high of $142.45. The company has a current ratio of 4.01, a quick ratio of 3.99 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $17,594.12, a PE ratio of 100.03 and a beta of 0.66.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.54. Incyte had a negative net margin of 20.38% and a negative return on equity of 11.85%. The firm had revenue of $444.20 million for the quarter, compared to analyst estimates of $435.23 million. During the same period last year, the business earned $0.05 EPS. Incyte’s revenue for the quarter was up 36.0% compared to the same quarter last year. equities analysts expect that Incyte will post -0.21 EPS for the current year.

In other news, EVP Reid M. Huber sold 1,958 shares of Incyte stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $85.55, for a total value of $167,506.90. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider David W. Gryska sold 1,952 shares of Incyte stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $85.56, for a total transaction of $167,013.12. Following the completion of the sale, the insider now directly owns 12,922 shares in the company, valued at approximately $1,105,606.32. The disclosure for this sale can be found here. 17.20% of the stock is owned by insiders.

Several large investors have recently modified their holdings of INCY. Renaissance Technologies LLC purchased a new stake in shares of Incyte in the fourth quarter valued at about $71,639,000. HealthCor Management L.P. boosted its holdings in shares of Incyte by 125.5% in the fourth quarter. HealthCor Management L.P. now owns 1,350,000 shares of the biopharmaceutical company’s stock valued at $127,859,000 after acquiring an additional 751,450 shares in the last quarter. Sands Capital Management LLC boosted its holdings in shares of Incyte by 8.2% in the fourth quarter. Sands Capital Management LLC now owns 8,191,287 shares of the biopharmaceutical company’s stock valued at $775,797,000 after acquiring an additional 621,323 shares in the last quarter. Two Sigma Investments LP boosted its holdings in shares of Incyte by 143.1% in the fourth quarter. Two Sigma Investments LP now owns 729,107 shares of the biopharmaceutical company’s stock valued at $69,054,000 after acquiring an additional 429,181 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. boosted its holdings in Incyte by 527.4% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 471,468 shares of the biopharmaceutical company’s stock worth $44,653,000 after buying an additional 396,320 shares in the last quarter. 93.50% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/incyte-incy-pt-set-at-85-00-by-raymond-james-financial.html.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply